University of Groningen

Insight into the Severity of Adverse Drug Reactions as Experienced by Patients

Rolfes, Leàn; Haaksman, Michelle; van Hunsel, Florence; van Puijenbroek, Eugène

Published in:
Drug Safety

DOI:
[10.1007/s40264-019-00890-7](https://doi.org/10.1007/s40264-019-00890-7)

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version
Publisher's PDF, also known as Version of record

Publication date:
2020

[Link to publication in University of Groningen/UMCG research database](#)

Citation for published version (APA):

Rolfes, L., Haaksman, M., van Hunsel, F., & van Puijenbroek, E. (2020). Insight into the Severity of Adverse Drug Reactions as Experienced by Patients. *Drug Safety*, 43(3), 291–293.
<https://doi.org/10.1007/s40264-019-00890-7>

Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license. More information can be found on the University of Groningen website: <https://www.rug.nl/library/open-access/self-archiving-pure/taverne-amendment>.

Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): <http://www.rug.nl/research/portal>. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.

Insight into the Severity of Adverse Drug Reactions as Experienced by Patients

Leàn Rolfes¹ · Michelle Haaksman¹ · Florence van Hunsel¹ · Eugène van Puijenbroek^{1,2}

Published online: 13 December 2019
© Springer Nature Switzerland AG 2019

Dear Editor,

Experiencing adverse drug reactions (ADRs) may have a great impact on the patient's well-being, attitudes and beliefs regarding medicines [1–3]. In the regulatory setting, serious ADRs are often prioritised, for example those leading to hospitalization. Medical seriousness can, however, differ from patients' views on what constitutes a serious problem [4]. Insight into how patients experience the severity of ADRs may help healthcare professionals to understand how patients feel [1, 5]. It can also help to better assess for what type of ADRs patients need more information. Systematically gathering data about the severity of ADRs by pharmacovigilance centres is still uncommon. Following previous research by Lareb [6], the question 'How severe was the ADR?'—with a 5-point Likert scale answer option ranging from 'none at all' to 'extremely'—was added to the existing patient reporting form.

We explored data collected in the first year this 'severity question' was in place on the reporting form in order to get an impression about differences in experienced severity for ADRs. We retrospectively analysed the severity scores of all serious versus non-serious ADRs reported to Lareb by patients between 10 July 2017 and 10 July 2018. Analysis was based on ADR (Higher Level Term, minimal 20 reports), outcome of the ADR (recovered vs. not recovered) and the action taken on the suspected drug (continued vs. discontinued). The dataset included 2969 ADR reports, including 7769 drug–ADR associations, of which 205

(2.6%) were serious ADRs and 7564 (97.3%) non-serious ADRs.

Serious ADRs had an average severity score of 4.7 versus 3.4 for non-serious ADRs (Fig. 1; Pearson's Chi-squared test $p < 0.001$). For an in-depth analysis we focused on non-serious ADRs as, compared with medically serious ADRs, less is known about the impact of non-serious ADRs.

Behaviour and socialisation disturbances (e.g. aggression) had the highest severity grading (4.7), followed by *suicidal and self-injurious behaviour* (4.6). ADRs with the lowest severity grading were *injection-site reactions* (2.9) and *vulvovaginal disorders* (3.0).

Patients who did not recover from the ADR more often reported the categories 'slightly' (9.3% vs. 4.4%; $p < 0.001$), 'moderately' (27.2% vs. 16.8%; $p < 0.001$), and 'very' (29.1% vs. 27.2%; $p = 0.011$). The category 'extremely' was more often reported by patients who recovered from the ADR (51.3% vs. 34.1%; $p < 0.001$). This may imply that patients who did not recover accepted the burden of the ADR. Another possible explanation for this difference could be a difference in motive for reporting.

Figure 2 demonstrates the severity based on the action taken on the drug use and the outcome of the ADR. The action taken on the drug can, for example, be use is continued, the dose is decreased or the drug use is discontinued. In this analysis we included the actions 'continued with drug use' and 'discontinued with drug use'. We compared this with the outcomes of the ADR 'the ADR recovered' and 'the ADR did not recover'. Patients who continued the drug use more often reported the categories 'none at all' (0.5% vs. 0.2%; $p < 0.001$), 'slightly' (20.8% vs. 13.5%; $p < 0.001$) and 'moderately' (32.4% vs. 15.1%; $p < 0.001$). The category 'extremely' was more often reported by patients who discontinued the drug (54.3% vs. 24.8%; $p < 0.001$).

Our analysis shows that patients' experiences can differ from what is considered medically important. Also, non-serious ADRs can have a severe burden for the patient. We believe information about the severity can be useful for

✉ Leàn Rolfes
L.rolfes@lareb.nl

¹ Netherlands Pharmacovigilance Centre Lareb,
Goudsbloemvallei 7, 5237 MH 's-Hertogenbosch,
The Netherlands

² Unit of Pharmacotherapy, -Epidemiology and -Economics,
Groningen Research Institute of Pharmacy, University
of Groningen, Groningen, The Netherlands

Fig. 1 Severity of serious versus non-serious adverse drug reactions (ADRs)

Fig. 2 Severity based on the action taken on the drug use and the outcome of the adverse drug reaction (ADR)

signal management, for example for prioritising for what type of ADRs patients need more information. It would be beneficial to have an objective standardised measure developed that could be used by pharmacovigilance centres across the world. But before such a standard is developed and in place, we would like to stimulate others to engage in generating knowledge about the severity of ADRs since this is not yet common practice. Thereafter, initial steps would be to explore how to use this information for signal management purposes, and to identify the ADRs with the largest burden for patients.

Compliance with Ethical Standards

Funding No sources of funding were used to assist in the preparation of this study.

Conflict of interest Leàn Rolfes, Michelle Haaksman, Florence van Hunsel and Eugène van Puijenbroek declare that they have no conflicts of interest that are directly relevant to the content of this study.

References

1. Baiardini I, Gaeta F, Molinengo G, Braido F, Canonica GW, Romano A. Quality-of-life issues in survivors to anaphylactic reactions to drugs. *Allergy*. 2015;70(7):877–9.
2. Baldessarini RJ, Perry R, Pike J. Factors associated with treatment nonadherence among US bipolar disorder patients. *Hum Psychopharmacol*. 2008;23(2):95–105.
3. Kwara A, Herold JS, Machan JT, Carter EJ. Factors associated with failure to complete isoniazid treatment for latent tuberculosis infection in Rhode Island. *Chest*. 2008;133(4):862–8.
4. van Hunsel F. The contribution of direct patient reporting to pharmacovigilance. Groningen: University of Groningen; 2011.
5. Golomb BA, McGraw JJ, Evans MA, Dimsdale JE. Physician response to patient reports of adverse drug effects: implications for patient-targeted adverse effect surveillance. *Drug Saf*. 2007;30(8):669–75.
6. Rolfes L, van Hunsel F, Taxis K, van Puijenbroek E. The impact of experiencing adverse drug reactions on the patient's quality of life: a retrospective cross-sectional study in the Netherlands. *Drug Saf*. 2016;39(8):769–76.